RU2011113996A - Способы визуализации и радиотерапии - Google Patents
Способы визуализации и радиотерапии Download PDFInfo
- Publication number
- RU2011113996A RU2011113996A RU2011113996/15A RU2011113996A RU2011113996A RU 2011113996 A RU2011113996 A RU 2011113996A RU 2011113996/15 A RU2011113996/15 A RU 2011113996/15A RU 2011113996 A RU2011113996 A RU 2011113996A RU 2011113996 A RU2011113996 A RU 2011113996A
- Authority
- RU
- Russia
- Prior art keywords
- alkyl
- formula
- compound
- fluoroc
- iodine
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract 31
- 238000012800 visualization Methods 0.000 title claims 4
- 238000001959 radiotherapy Methods 0.000 title claims 3
- 150000001875 compounds Chemical class 0.000 claims abstract 42
- 229910052740 iodine Inorganic materials 0.000 claims abstract 24
- -1 Co Inorganic materials 0.000 claims abstract 15
- 150000003839 salts Chemical class 0.000 claims abstract 13
- 239000012453 solvate Substances 0.000 claims abstract 13
- 108020002663 Aldehyde Dehydrogenase Proteins 0.000 claims abstract 10
- 238000003384 imaging method Methods 0.000 claims abstract 8
- 239000000758 substrate Substances 0.000 claims abstract 8
- 206010028980 Neoplasm Diseases 0.000 claims abstract 5
- 238000012634 optical imaging Methods 0.000 claims abstract 4
- 238000002600 positron emission tomography Methods 0.000 claims abstract 4
- 238000002603 single-photon emission computed tomography Methods 0.000 claims abstract 4
- 238000001727 in vivo Methods 0.000 claims abstract 3
- 102000005369 Aldehyde Dehydrogenase Human genes 0.000 claims abstract 2
- 229910052799 carbon Inorganic materials 0.000 claims abstract 2
- 238000011503 in vivo imaging Methods 0.000 claims abstract 2
- 239000002184 metal Substances 0.000 claims abstract 2
- 229910052751 metal Inorganic materials 0.000 claims abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract 2
- 230000003287 optical effect Effects 0.000 claims abstract 2
- 230000002285 radioactive effect Effects 0.000 claims abstract 2
- 210000000130 stem cell Anatomy 0.000 claims abstract 2
- 125000000217 alkyl group Chemical group 0.000 claims 54
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims 23
- 239000011630 iodine Substances 0.000 claims 23
- 125000003545 alkoxy group Chemical group 0.000 claims 20
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 16
- 229910052739 hydrogen Inorganic materials 0.000 claims 9
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims 8
- 125000004093 cyano group Chemical group *C#N 0.000 claims 8
- 125000005843 halogen group Chemical group 0.000 claims 8
- 239000001257 hydrogen Substances 0.000 claims 8
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 8
- 125000001424 substituent group Chemical group 0.000 claims 8
- 125000002346 iodo group Chemical group I* 0.000 claims 6
- 125000003118 aryl group Chemical group 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 2
- NCZATIGICHVWLM-HSGWXFLFSA-N 4-[2-(18F)fluoranylethyl(propyl)amino]benzaldehyde Chemical compound [18F]CCN(C1=CC=C(C=O)C=C1)CCC NCZATIGICHVWLM-HSGWXFLFSA-N 0.000 claims 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical group [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 claims 1
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 claims 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- 229910052796 boron Chemical group 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 239000007850 fluorescent dye Substances 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 125000001041 indolyl group Chemical group 0.000 claims 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims 1
- 238000012544 monitoring process Methods 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000001301 oxygen Chemical group 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 1
- 230000003439 radiotherapeutic effect Effects 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 239000011593 sulfur Chemical group 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 229910052688 Gadolinium Inorganic materials 0.000 abstract 2
- 229910052738 indium Inorganic materials 0.000 abstract 2
- 229910052791 calcium Inorganic materials 0.000 abstract 1
- 229910052802 copper Inorganic materials 0.000 abstract 1
- 229910052742 iron Inorganic materials 0.000 abstract 1
- 238000009877 rendering Methods 0.000 abstract 1
- 229910052713 technetium Inorganic materials 0.000 abstract 1
- 229910052720 vanadium Inorganic materials 0.000 abstract 1
- 0 *c(cc1)ccc1C(NCCC=O)=O Chemical compound *c(cc1)ccc1C(NCCC=O)=O 0.000 description 2
- WEAKVBPGCWZRSD-UHFFFAOYSA-N Cc1cccc2c1[nH]c(C=O)c2 Chemical compound Cc1cccc2c1[nH]c(C=O)c2 WEAKVBPGCWZRSD-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0446—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Radiology & Medical Imaging (AREA)
- Medical Informatics (AREA)
- Pathology (AREA)
- Surgery (AREA)
- High Energy & Nuclear Physics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Radiation-Therapy Devices (AREA)
- Indole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10700108P | 2008-10-21 | 2008-10-21 | |
| GB0819280.9 | 2008-10-21 | ||
| US61/107,001 | 2008-10-21 | ||
| GBGB0819280.9A GB0819280D0 (en) | 2008-10-21 | 2008-10-21 | Imgaing and radiotherapy methods |
| PCT/US2009/061271 WO2010048144A2 (en) | 2008-10-21 | 2009-10-20 | Imaging and radiotherapy methods |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2011113996A true RU2011113996A (ru) | 2012-11-27 |
Family
ID=40097766
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2011113996/15A RU2011113996A (ru) | 2008-10-21 | 2009-10-20 | Способы визуализации и радиотерапии |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20110286922A1 (enExample) |
| EP (1) | EP2349351A2 (enExample) |
| JP (1) | JP2012506439A (enExample) |
| KR (1) | KR20110074988A (enExample) |
| CN (1) | CN102186505A (enExample) |
| AU (1) | AU2009307783A1 (enExample) |
| BR (1) | BRPI0919690A2 (enExample) |
| CA (1) | CA2738955A1 (enExample) |
| GB (1) | GB0819280D0 (enExample) |
| MX (1) | MX2011004161A (enExample) |
| RU (1) | RU2011113996A (enExample) |
| WO (1) | WO2010048144A2 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1729824T3 (da) | 2004-03-02 | 2009-11-02 | Cellectar Inc | Phospholipidanaloger til behandling af cancere |
| US8540968B2 (en) | 2004-03-02 | 2013-09-24 | Cellectar, Inc. | Phospholipid ether analogs as agents for detecting and locating cancer, and methods thereof |
| CU23844B1 (es) * | 2009-04-17 | 2012-10-15 | Ct De Neurociencias De Cuba | Procedimiento de obtención de nuevos derivados de naftaleno para el diagnóstico in vivo de la enfermedad de alzheimer |
| RU2012100765A (ru) * | 2009-06-12 | 2013-07-20 | Селлектар, Инк. | Эфирные и алкильные фосфолипидные производные для лечения рака и визуализации и детектирования раковых стволовых клеток |
| CN102725003A (zh) * | 2009-12-22 | 2012-10-10 | 通用电气健康护理有限公司 | 用于癌症干细胞中的人体肝脏醛脱氢酶进行体内成像的醛类化合物 |
| WO2012074840A2 (en) | 2010-11-22 | 2012-06-07 | The General Hospital Corporation | Compositions and methods for in vivo imaging |
| WO2013012754A1 (en) * | 2011-07-15 | 2013-01-24 | University Of Southern California | Boron-based dual imaging probes, compositions and methods for rapid aqueous f-18 labeling, and imaging methods using same |
| WO2013048832A1 (en) * | 2011-09-29 | 2013-04-04 | Ge Healthcare Limited | 18 f - labelled 6 - ( 2 - fluoroethoxy) - 2 - naphthaldehyde for detecting cancer stem cells |
| WO2013048811A1 (en) * | 2011-09-30 | 2013-04-04 | Ge Healthcare Limited | Imaging and radiotherapy methods for tumour stem cells |
| US8927732B2 (en) * | 2012-03-30 | 2015-01-06 | General Electric Company | Biotin stannane for HPLC-free radioiodination |
| WO2014145493A1 (en) * | 2013-03-15 | 2014-09-18 | The Johns Hopkins University | Radioactive substrates for aldehyde dehydrogenase |
| WO2017187717A1 (ja) * | 2016-04-28 | 2017-11-02 | 国立大学法人名古屋大学 | 蛍光プローブ、蛍光検出方法及び蛍光プローブの使用方法 |
| FR3054564B1 (fr) * | 2016-07-28 | 2018-08-31 | Advanced Biodesign | Substrat specifique d'une isoenzyme de l'aldh |
| KR101941223B1 (ko) * | 2017-04-04 | 2019-01-22 | 을지대학교 산학협력단 | 복강경 수술용 삼중 융합영상장치 |
| JP2023025307A (ja) * | 2020-01-31 | 2023-02-22 | 国立大学法人 東京大学 | アルデヒドロゲナーゼ１ａ１検出用青色蛍光プローブ |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5876956A (en) * | 1995-05-15 | 1999-03-02 | Johns Hopkins University School Of Medicine | Methods for identification or purification of cells containing an enzymatic intracellular marker |
| AU2003228744A1 (en) * | 2002-04-29 | 2003-11-17 | The Ohio State University | Inhibition of protein tyrosine phosphatases and sh2 domains by a neutral phosphotyrosine mimetic |
| GB0305704D0 (en) * | 2003-03-13 | 2003-04-16 | Amersham Plc | Radiofluorination methods |
| GB0502277D0 (en) * | 2005-02-04 | 2005-03-09 | Amersham Plc | Novel imaging agents |
| US20080058316A1 (en) * | 2006-02-27 | 2008-03-06 | The Johns Hopkins University | Cancer treatment with gama-secretase inhibitors |
| US20080187938A1 (en) * | 2006-09-22 | 2008-08-07 | The Regents Of The University Of Michigan | ALDH1 As A Cancer Stem Cell Marker |
-
2008
- 2008-10-21 GB GBGB0819280.9A patent/GB0819280D0/en not_active Ceased
-
2009
- 2009-10-20 MX MX2011004161A patent/MX2011004161A/es not_active Application Discontinuation
- 2009-10-20 RU RU2011113996/15A patent/RU2011113996A/ru not_active Application Discontinuation
- 2009-10-20 US US13/124,703 patent/US20110286922A1/en not_active Abandoned
- 2009-10-20 CA CA2738955A patent/CA2738955A1/en not_active Abandoned
- 2009-10-20 EP EP09749242A patent/EP2349351A2/en not_active Withdrawn
- 2009-10-20 CN CN2009801423890A patent/CN102186505A/zh active Pending
- 2009-10-20 AU AU2009307783A patent/AU2009307783A1/en not_active Abandoned
- 2009-10-20 BR BRPI0919690A patent/BRPI0919690A2/pt not_active IP Right Cessation
- 2009-10-20 JP JP2011533266A patent/JP2012506439A/ja active Pending
- 2009-10-20 KR KR1020117008974A patent/KR20110074988A/ko not_active Withdrawn
- 2009-10-20 WO PCT/US2009/061271 patent/WO2010048144A2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| JP2012506439A (ja) | 2012-03-15 |
| WO2010048144A2 (en) | 2010-04-29 |
| KR20110074988A (ko) | 2011-07-05 |
| CN102186505A (zh) | 2011-09-14 |
| CA2738955A1 (en) | 2010-04-29 |
| WO2010048144A3 (en) | 2010-07-22 |
| BRPI0919690A2 (pt) | 2015-12-08 |
| GB0819280D0 (en) | 2008-11-26 |
| AU2009307783A1 (en) | 2010-04-29 |
| US20110286922A1 (en) | 2011-11-24 |
| EP2349351A2 (en) | 2011-08-03 |
| MX2011004161A (es) | 2011-06-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2011113996A (ru) | Способы визуализации и радиотерапии | |
| JP2012506439A5 (enExample) | ||
| EP2764406B1 (en) | Compositions and methods for tumor imaging and targeting by a class of organic heptamethine cyanine dyes that possess dual nuclear and near-infrared properties | |
| Kung et al. | In vitro and in vivo evaluation of [123I] IBZM: a potential CNS D-2 dopamine receptor imaging agent | |
| JP2008546783A (ja) | 腫瘍画像化のためのアミノ酸類似体の立体選択的合成 | |
| Cao et al. | Intensity enhanced Cerenkov luminescence imaging using terbium-doped Gd2O2S microparticles | |
| MX2010012636A (es) | Nuevos derivados de acido l-glutamico y l-glutamina marcados con [f-18] (i), su uso y procedimiento para su preparacion. | |
| Basu et al. | Metastatic neuroendocrine tumor with extensive bone marrow involvement at diagnosis: evaluation of response and hematological toxicity profile of PRRT with 177Lu-DOTATATE | |
| CN102413844B (zh) | 标记的分子成像剂、制备方法及使用方法 | |
| JPH10500942A (ja) | ポルフォシアニン及びｃｎｃ−展開ポルフィリン | |
| Banerjee et al. | A novel [186/188Re]-labelled porphyrin for targeted radiotherapy | |
| CN103951668A (zh) | 叶酸衍生物的正电子核素标记物及其应用 | |
| WO2022242437A1 (zh) | 一种荧光-磁共振双模态造影剂及其制备方法和用途 | |
| US7674902B2 (en) | Luminescent metal complexes for monitoring renal function | |
| Quastel et al. | Tumour scanning with indium-111 dihaematoporphyrin ether | |
| CN105214103B (zh) | 用于恶性肿瘤和心脑血管相关疾病早期快速检测及多模态成像的金属离子试剂和影像制剂 | |
| KR101519006B1 (ko) | 신규한 벤즈아마이드 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 피부암 진단용 약학적 조성물 | |
| CN114805417B (zh) | 一种核素标记的鸟氨酸及其制备方法和应用 | |
| CN109438265B (zh) | 一种与棕色脂肪组织具有亲和力的化合物及其制备方法和应用 | |
| Kumata et al. | Radiosynthesis of 13N‐labeled thalidomide using no‐carrier‐added [13N] NH3 | |
| WO2025145255A1 (en) | Lat-1 targeting amino acid derivatives and uses thereof | |
| CN121532406A (zh) | 一种成纤维细胞活化蛋白配体及其用途 | |
| JPWO2017002754A1 (ja) | 蛍光色素を用いた歯周病の簡易検査 | |
| KR100962267B1 (ko) | 폴피린 유도체, 그 제조방법, 및 그것을 포함하는 약제학적조성물 | |
| CN120817928A (zh) | 一种非环螯合剂及其制备方法与应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20140813 |